| Project/Area Number |
15K15310
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中神 太志 大阪大学, 医学部附属病院, 助教 (60739176)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ワクチン / 免疫治療 / MDSC / MRP14 / 慢性炎症 |
|---|
| Outline of Final Research Achievements |
MRP8/14 (S100A8/A9) is highly expressed in MDSC cells and induces inframmatory cytokines. To examine the potential role of MRP8/14, we developed a peptide vaccine which is composed of KLH and a B-cell epitope of MRP8/14. After immuinization, anti- MRP8/14 antibody titer was increased and sustained for more than two months after injection of vaccine. Importantly, it could suppress thrombus formation in middle cerebral arteries in mice for at least 2 months without affecting hemostatic parameters. Although S100A9 forms heterodimer with S100A8, the vaccine for S100A8 showed no effects. Thus, S100A9 antithrombotic vaccine might be a novel strategy to prevent recurrent strokes in non-adherent patients.
|
